Trade Summary

5 days ago, Piekos Brian, serving as Chief Financial Officer at KalVista Pharmaceuticals, Inc. (KALV), sold 1,489 shares at $26.78 per share, for a total transaction value of $39,881.97. Following this transaction, Piekos Brian now holds 21,661 shares of KALV.

This sale represents a 6.43% decrease in Piekos Brian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, May 22, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 26, 2026 at 7:32 PM ET, 4 days after the trade was made.

KalVista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.